JP2021535216A - セバコイルジナルブフィンとアセトアミノフェンの医薬品製剤及び疼痛を治療する方法 - Google Patents
セバコイルジナルブフィンとアセトアミノフェンの医薬品製剤及び疼痛を治療する方法 Download PDFInfo
- Publication number
- JP2021535216A JP2021535216A JP2021536123A JP2021536123A JP2021535216A JP 2021535216 A JP2021535216 A JP 2021535216A JP 2021536123 A JP2021536123 A JP 2021536123A JP 2021536123 A JP2021536123 A JP 2021536123A JP 2021535216 A JP2021535216 A JP 2021535216A
- Authority
- JP
- Japan
- Prior art keywords
- analgesic
- pharmaceutical preparation
- composition
- agent
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (15)
- セバコイルジナルブフィン(sebacoyl dinalbuphine)又はその代謝産物や派生物である治療有効量の第1鎮痛剤及び/又は、
アセトアミノフェン(acetaminophen、AAP)又はその派生物である治療有効量の第2鎮痛剤と、
一つ又は複数の薬学的に許容される賦形剤と
を含む
ことを特徴とする鎮痛剤の医薬品製剤。 - 前記一つ又は複数の薬学的に許容される賦形剤は、Eudragit S100、脱水リン酸二カルシウム(Dicalcium phosphate dehydrate)、Pluronic F68、ヘキシトール(Hexitol)、クロスポビドン(Crospovidone)、デンプングリコール酸ナトリウム(Sodium starch glycolate)、Aerosil 200、トリクロロスクロース(Trichlorosucrose)、メントール(Menthol)、サッカリン(Saccharin)、安息香酸ナトリウム(Sodium benzoate)、ベヘン酸グリセリル(Glyceryl behenate)、ラウリル硫酸ナトリウム(Sodium lauryl sulfate)、Providone K30、及びこれらの複合体からなる群より選択される
ことを特徴とする請求項1に記載の医薬品製剤。 - 前記第1鎮痛剤と前記第2鎮痛剤との組み合わせを含む
ことを特徴とする請求項1に記載の医薬品製剤。 - 前記第1鎮痛剤は、遊離塩基の形のセバコイルジナルブフィン(sebacoyl dinalbuphine)又は薬学的に許容される塩である
ことを特徴とする請求項1に記載の医薬品製剤。 - (i)セバコイルジナルブフィン(sebacoyl dinalbuphine)又はその代謝産物や派生物である治療有効量の第1鎮痛剤を含む第1鎮痛剤組成物と、
(ii)アセトアミノフェン(acetaminophen、AAP)又はその派生物である治療有効量の第2鎮痛剤を含む第2鎮痛剤組成物と
を含む
ことを特徴とする鎮痛剤の医薬品製剤。 - Eudragit S100、脱水リン酸二カルシウム(Dicalcium phosphate dehydrate)、Pluronic F68、ヘキシトール(Hexitol)、クロスポビドン(Crospovidone)、デンプングリコール酸ナトリウム(Sodium starch glycolate)、Aerosil 200、トリクロロスクロース(Trichlorosucrose)、メントール(Menthol)、 サッカリン(Saccharin)、安息香酸ナトリウム(Sodium benzoate)、ベヘン酸グリセリル(Glyceryl behenate)、ラウリル硫酸ナトリウム(Sodium lauryl sulfate)、Providone K30、及びこれらの組み合わせからなる群より選択された一つ又は複数の薬学的に許容される賦形剤を含む
ことを特徴とする請求項5に記載の医薬品製剤。 - キャリア及びバランスとして一つ又は複数の追加の賦形剤をさらに含む
ことを特徴とする請求項6に記載の医薬品製剤。 - 前記第1鎮痛剤と前記第2鎮痛剤の量は、0〜1000mgである
ことを特徴とする請求項5に記載の医薬品製剤。 - 総合・相乗的な(summation/synergistic)鎮痛効果を提供する
ことを特徴とする請求項5に記載の医薬品製剤。 - 前記第1鎮痛剤組成物又は前記第2鎮痛剤組成物をそれぞれ比較した場合、前記総合・相乗的な鎮痛効果は、より高い有効性、より速い鎮痛効果の発生、及び/又はより長い鎮痛効果の期間を含む
ことを特徴とする請求項9に記載の医薬品製剤。 - 前記第1鎮痛剤組成物における前記第1鎮痛剤又は前記第2鎮痛剤組成物における前記第2鎮痛剤をそれぞれ比較した場合の値は、前記総合・相乗的な鎮痛効果に含む前記第1鎮痛剤組成物における前記第1鎮痛剤と前記第2鎮痛剤組成物における前記第2鎮痛剤の一つ又は複数の薬物動態パラメーターの量が増加する
ことを特徴とする請求項9に記載の医薬品製剤。 - 前記第1鎮痛剤は、遊離塩基の形のセバコイルジナルブフィン(sebacoyl dinalbuphine)又は薬学的に許容される塩である
ことを特徴とする請求項5に記載の医薬品製剤。 - 前記鎮痛剤組成物は、ゲル、スプレー、エマルジョン、トローチ剤、分散性錠剤、錠剤、腸溶性コーティング剤、カプセル、ソフトカプセル剤、顆粒、懸濁液、ミクロスフェア、口腔インプラント、筋肉注射、静脈注射、埋め込み型注射、放出調節剤、及び他の薬学的に許容される形態で投与される
ことを特徴とする請求項1〜12のいずれかに記載の医薬品製剤。 - 請求項1〜13のいずれかに記載の鎮痛剤の医薬品製剤を個体に投与することを含む
ことを特徴とする必要がある個体の疼痛を治療する方法。 - 必要がある個体の疼痛を治療するための薬剤を製造する
ことを特徴とする請求項1〜13のいずれかに記載の鎮痛剤の医薬品製剤の用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023060264A JP2023078480A (ja) | 2018-09-03 | 2023-04-03 | セバコイルジナルブフィンとアセトアミノフェンの医薬品製剤及び疼痛を治療する方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/103786 WO2020047703A1 (en) | 2018-09-03 | 2018-09-03 | Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023060264A Division JP2023078480A (ja) | 2018-09-03 | 2023-04-03 | セバコイルジナルブフィンとアセトアミノフェンの医薬品製剤及び疼痛を治療する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021535216A true JP2021535216A (ja) | 2021-12-16 |
JP7318987B2 JP7318987B2 (ja) | 2023-08-01 |
Family
ID=69721971
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021536123A Active JP7318987B2 (ja) | 2018-09-03 | 2018-09-03 | セバコイルジナルブフィンとアセトアミノフェンの医薬品製剤及び疼痛を治療する方法 |
JP2023060264A Pending JP2023078480A (ja) | 2018-09-03 | 2023-04-03 | セバコイルジナルブフィンとアセトアミノフェンの医薬品製剤及び疼痛を治療する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023060264A Pending JP2023078480A (ja) | 2018-09-03 | 2023-04-03 | セバコイルジナルブフィンとアセトアミノフェンの医薬品製剤及び疼痛を治療する方法 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3846815A4 (ja) |
JP (2) | JP7318987B2 (ja) |
KR (1) | KR20210054560A (ja) |
CN (1) | CN113164469A (ja) |
AU (1) | AU2018440280B2 (ja) |
CA (1) | CA3111271A1 (ja) |
CL (1) | CL2021000309A1 (ja) |
IL (1) | IL280822A (ja) |
SG (1) | SG11202101974WA (ja) |
WO (1) | WO2020047703A1 (ja) |
ZA (1) | ZA202102209B (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55154917A (en) * | 1979-05-18 | 1980-12-02 | Du Pont | Analgesic mixture |
US6225321B1 (en) * | 1997-06-05 | 2001-05-01 | Oliver Yoa-Pu Hu | Long analgesic acting nalbuphine polyester derivative and method of use |
WO2004054511A2 (en) * | 2002-12-13 | 2004-07-01 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
WO2008107410A1 (en) * | 2007-03-02 | 2008-09-12 | Flamek Corp Oü | Analgesic composition of topically applied nonsteroidal antiinflammatory drugs and opioids |
JP2016520100A (ja) * | 2013-11-13 | 2016-07-11 | ▲財▼▲団▼法人国防教育研究基金会National Defense Education And Research Foundation | 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成 |
-
2018
- 2018-09-03 AU AU2018440280A patent/AU2018440280B2/en active Active
- 2018-09-03 SG SG11202101974WA patent/SG11202101974WA/en unknown
- 2018-09-03 WO PCT/CN2018/103786 patent/WO2020047703A1/en unknown
- 2018-09-03 CA CA3111271A patent/CA3111271A1/en active Pending
- 2018-09-03 CN CN201880096947.3A patent/CN113164469A/zh active Pending
- 2018-09-03 EP EP18932827.1A patent/EP3846815A4/en active Pending
- 2018-09-03 JP JP2021536123A patent/JP7318987B2/ja active Active
- 2018-09-03 KR KR1020217009905A patent/KR20210054560A/ko not_active Application Discontinuation
-
2021
- 2021-02-05 CL CL2021000309A patent/CL2021000309A1/es unknown
- 2021-02-11 IL IL280822A patent/IL280822A/en unknown
- 2021-03-31 ZA ZA2021/02209A patent/ZA202102209B/en unknown
-
2023
- 2023-04-03 JP JP2023060264A patent/JP2023078480A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55154917A (en) * | 1979-05-18 | 1980-12-02 | Du Pont | Analgesic mixture |
US6225321B1 (en) * | 1997-06-05 | 2001-05-01 | Oliver Yoa-Pu Hu | Long analgesic acting nalbuphine polyester derivative and method of use |
WO2004054511A2 (en) * | 2002-12-13 | 2004-07-01 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
WO2008107410A1 (en) * | 2007-03-02 | 2008-09-12 | Flamek Corp Oü | Analgesic composition of topically applied nonsteroidal antiinflammatory drugs and opioids |
JP2016520100A (ja) * | 2013-11-13 | 2016-07-11 | ▲財▼▲団▼法人国防教育研究基金会National Defense Education And Research Foundation | 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成 |
Also Published As
Publication number | Publication date |
---|---|
EP3846815A1 (en) | 2021-07-14 |
JP7318987B2 (ja) | 2023-08-01 |
CL2021000309A1 (es) | 2021-07-19 |
KR20210054560A (ko) | 2021-05-13 |
CA3111271A1 (en) | 2020-03-12 |
AU2018440280A1 (en) | 2021-03-18 |
EP3846815A4 (en) | 2022-05-04 |
IL280822A (en) | 2021-04-29 |
SG11202101974WA (en) | 2021-03-30 |
WO2020047703A1 (en) | 2020-03-12 |
JP2023078480A (ja) | 2023-06-06 |
AU2018440280B2 (en) | 2022-11-03 |
CN113164469A (zh) | 2021-07-23 |
ZA202102209B (en) | 2022-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8969400B2 (en) | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | |
JP5363152B2 (ja) | グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置 | |
JP6891385B2 (ja) | トラジピタントによる治療方法 | |
Desager | Clinical pharmacokinetics of ticlopidine | |
JP2002507962A (ja) | トラマドールとnmdaの組合せによる痛み軽減法 | |
JP6336592B2 (ja) | ヒスタミンh4受容体を介してもたらされた掻痒状態を治療するための医薬組成物 | |
US6512009B1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator | |
JP2011168580A (ja) | 医薬組成物 | |
JP2019023195A (ja) | L−4−クロロキヌレニンの剤形及び治療的使用 | |
US20230181583A1 (en) | Treating liver disorders with an ssao inhibitor | |
AU2023251499A1 (en) | Combinations of opioids and N-acylethanolamines | |
US20200069675A1 (en) | Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain | |
JP2021535216A (ja) | セバコイルジナルブフィンとアセトアミノフェンの医薬品製剤及び疼痛を治療する方法 | |
TW202010496A (zh) | 双那布扶林己二酸酯和乙醯胺酚的藥物製劑及治療疼痛的方法 | |
BR112021014342A2 (pt) | Uso de um antagonista mglur5 para tratar tolerância a analgésico opioide | |
AU2022384271A1 (en) | Treating liver disorders with an ssao inhibitor | |
JP6027916B2 (ja) | ロキソプロフェン含有医薬組成物 | |
EA046106B1 (ru) | ПРИМЕНЕНИЕ АНТАГОНИСТА mGluR5 ДЛЯ ЛЕЧЕНИЯ ТОЛЕРАНТНОСТИ К ОПИОИДНЫМ АНАЛЬГЕТИКАМ | |
JP2009502828A (ja) | Nmda受容体遮断薬と麻薬性鎮痛物質とを含む治療用組合せ | |
BR102014003686B1 (pt) | Composição farmacêutica oral estável | |
BR102013032395A2 (pt) | Composição farmacêutica oral estável |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220725 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230403 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230403 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230411 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230418 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230616 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230627 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230712 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7318987 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |